tiprankstipranks
Sangamo Therapeutics (SGMO)
NASDAQ:SGMO
US Market
SGMO
Sangamo Therapeutics
RESEARCH TOOLSreports

Sangamo Therapeutics (SGMO) Financial Statements

2,627 Followers

Sangamo Therapeutics Financial Overview

Sangamo Therapeutics's market cap is currently $104.07M. The company's EPS TTM is $-0.11; its P/E ratio is -0.95; Sangamo Therapeutics is scheduled to report earnings on March 30, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue$ 39.55M$ 57.80M$ 176.23M$ 111.30M$ 110.70M
Gross Profit$ 31.95M$ 57.80M$ 176.23M$ 99.19M$ 110.70M
Operating Income$ -108.00M$ -103.97M$ -274.00M$ -201.28M$ -183.34M
EBITDA$ -100.40M$ -89.09M$ -96.80M$ -189.17M$ -165.70M
Net Income$ -122.93M$ -97.94M$ -257.83M$ -192.28M$ -178.29M
Balance Sheet
Cash & Short-Term Investments$ 20.95M$ 41.92M$ 81.00M$ 277.63M$ 376.55M
Total Assets$ 59.74M$ 101.64M$ 165.32M$ 562.51M$ 721.92M
Total Debt$ 26.80M$ 30.57M$ 38.10M$ 43.11M$ 48.08M
Net Debt$ 5.85M$ -11.35M$ -7.10M$ -57.34M$ -130.79M
Total Liabilities$ 74.01M$ 78.86M$ 82.43M$ 267.55M$ 346.58M
Stockholders' Equity$ -14.27M$ 22.77M$ 82.89M$ 294.96M$ 375.34M
Cash Flow
Free Cash Flow$ -97.31M$ -67.41M$ -246.00M$ -243.80M$ -256.53M
Operating Cash Flow$ -97.21M$ -67.14M$ -224.84M$ -223.63M$ -233.25M
Investing Cash Flow$ -102.00K$ 37.52M$ 153.53M$ 59.28M$ 248.20M
Financing Cash Flow$ 70.75M$ 28.38M$ 14.59M$ 84.66M$ 32.86M
Currency in USD

Sangamo Therapeutics Earnings and Revenue History

Income Statement >

Sangamo Therapeutics Debt to Assets

Balance Sheet >

Sangamo Therapeutics Cash Flow

Cash Flow >

Sangamo Therapeutics Forecast EPS vs Actual EPS

Earnings >